Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps

Pharmacology and Therapeutics

Volumn 166, Issue , 2016, Pages 30-39

  Beatty, Gregory L ^a   O'Hara, Mark ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CAR T cells; Cellular immunity; Chimeric antigen receptor; Solid malignancies; Tumor microenvironment

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; IMMUNOSUPPRESSIVE AGENT; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MESOTHELIN;

ARTICLE; CANCER IMMUNOTHERAPY; CELL EXPANSION; CELL MATURATION; CELL THERAPY; CELLULAR IMMUNITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE MIGRATION; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; NEOPLASMS; PHYSIOLOGY; PROCEDURES; PROTO ONCOGENE; SUICIDE TRANSGENE;

ANIMALS; GENES, ERBB-1; GENES, TRANSGENIC, SUICIDE; GPI-LINKED PROTEINS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; TUMOR MICROENVIRONMENT;

EID: 84978886867     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.06.010     Document Type: Article

References (109)

1. Ahmed, N., Brawley, V.S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 33:15 (2015), 1688–1696.
2. Ali, K., Soond, D.R., Pineiro, R., Hagemann, T., Pearce, W., Lim, E.L., et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510:7505 (2014), 407–411.
3. Barrett, D.M., Liu, X., Jiang, S., June, C.H., Grupp, S.A., Zhao, Y., Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther 24:8 (2013), 717–727.
4. Bayne, L.J., Beatty, G.L., Jhala, N., Clark, C.E., Rhim, A.D., Stanger, B.Z., et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21:6 (2012), 822–835.
5. Beatty, G.L., Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma. Oncoimmunology, 3, 2014, e28327.
6. Beatty, G.L., Gladney, W.L., Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 21:4 (2015), 687–692.
7. Beatty, G.L., Chiorean, E.G., Fishman, M.P., Saboury, B., Teitelbaum, U.R., Sun, W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331:6024 (2011), 1612–1616.
8. Beatty, G.L., Haas, A.R., Maus, M.V., Torigian, D.A., Soulen, M.C., Plesa, G., et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol Res 2 (2014), 112–120.
9. Beatty, G.L., O'Hara, M.H., Nelson, A.M., McGarvey, M., Torigian, D.A., Lacey, S.F., et al. Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. J Clin Oncol, 33(15_suppl), 2015, 3007.
10. Beatty, G.L., Torigian, D.A., Chiorean, E.G., Saboury, B., Brothers, A., Alavi, A., et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 19:22 (2013), 6286–6295.
11. Beatty, G.L., Winograd, R., Evans, R.A., Long, K.B., Luque, S.L., Lee, J.W., et al. Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6C(low) F4/80(+) extratumoral macrophages. Gastroenterology 149:1 (2015), 201–210.
12. Berger, C., Flowers, M.E., Warren, E.H., Riddell, S.R., Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107:6 (2006), 2294–2302.
13. Bonecchi, R., Locati, M., Mantovani, A., Chemokines and cancer: a fatal attraction. Cancer Cell 19:4 (2011), 434–435.
14. Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276:5319 (1997), 1719–1724.
15. Bot, A., Rossi, J.M., Jiang, Y., Navale, L., Shen, Y.-w., Sherman, M., et al. Cyclophosphamide and fludarabine conditioning chemotherapy induces a key homeostatic cytokine profile in patients prior to CAR T cell therapy., 126, 2015, 4426.
16. Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med, 5(177), 2013, 177ra138.
17. Bronte, V., Zanovello, P., Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5:8 (2005), 641–654.
18. Brudno, J.N., Somerville, R.P., Shi, V., Rose, J.J., Halverson, D.C., Fowler, D.H., et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol 34:10 (2016), 1112–1121.
19. Buckanovich, R.J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 14:1 (2008), 28–36.
20. Cameron, B.J., Gerry, A.B., Dukes, J., Harper, J.V., Kannan, V., Bianchi, F.C., et al. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med, 5(197), 2013, 197ra103.
21. Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E.S., et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 21:5 (2015), 524–529.
22. Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 6(224), 2014, 224ra225.
23. Di Stasi, A., Tey, S.K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365:18 (2011), 1673–1683.
24. Dudley, M.E., Wunderlich, J.R., Yang, J.C., Sherry, R.M., Topalian, S.L., Restifo, N.P., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:10 (2005), 2346–2357.
25. Feig, C., Jones, J.O., Kraman, M., Wells, R.J., Deonarine, A., Chan, D.S., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 110:50 (2013), 20212–20217.
26. Fraietta, J.A., Beckwith, K.A., Patel, P.R., Ruella, M., Zheng, Z., Barrett, D.M., et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 127:9 (2016), 1117–1127.
27. Frank, O., Rudolph, C., Heberlein, C., von Neuhoff, N., Schrock, E., Schambach, A., et al. Tumor cells escape suicide gene therapy by genetic and epigenetic instability. Blood 104:12 (2004), 3543–3549.
28. Gajewski, T.F., Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 13:18 Pt 1 (2007), 5256–5261.
29. Gajewski, T.F., Schreiber, H., Fu, Y.X., Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14:10 (2013), 1014–1022.
30. Galon, J., Angell, H.K., Bedognetti, D., Marincola, F.M., The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39:1 (2013), 11–26.
31. Gill, S., June, C.H., Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 263:1 (2015), 68–89.
32. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:16 (2013), 1509–1518.
33. Guest, R.D., Hawkins, R.E., Kirillova, N., Cheadle, E.J., Arnold, J., O'Neill, A., et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 28:3 (2005), 203–211.
34. Gunderson, A.J., Kaneda, M.M., Tsujikawa, T., Nguyen, A.V., Affara, N.I., Ruffell, B., et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov 6:3 (2016), 270–285.
35. Hegde, M., Corder, A., Chow, K.K., Mukherjee, M., Ashoori, A., Kew, Y., et al. Combinatorial targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 21:11 (2013), 2087–2101.
36. Huang, Y., Goel, S., Duda, D.G., Fukumura, D., Jain, R.K., Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 73:10 (2013), 2943–2948.
37. Huang, Y., Yuan, J., Righi, E., Kamoun, W.S., Ancukiewicz, M., Nezivar, J., et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 109:43 (2012), 17561–17566.
38. Hudecek, M., Lupo-Stanghellini, M.T., Kosasih, P.L., Sommermeyer, D., Jensen, M.C., Rader, C., et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 19:12 (2013), 3153–3164.
39. Jain, R.K., Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26:5 (2014), 605–622.
40. James, S.E., Greenberg, P.D., Jensen, M.C., Lin, Y., Wang, J., Till, B.G., et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol 180:10 (2008), 7028–7038.
41. John, L.B., Devaud, C., Duong, C.P., Yong, C.S., Beavis, P.A., Haynes, N.M., et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 19:20 (2013), 5636–5646.
42. Johnson, L.A., Morgan, R.A., Dudley, M.E., Cassard, L., Yang, J.C., Hughes, M.S., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:3 (2009), 535–546.
43. Johnson, L.A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P.R., McGettigan, S.E., et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med, 7(275), 2015, 275ra222.
44. Joyce, J.A., Fearon, D.T., T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:6230 (2015), 74–80.
45. Katz, S.C., Burga, R.A., McCormack, E., Wang, L.J., Mooring, W., Point, G.R., et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA + liver metastases. Clin Cancer Res 21:14 (2015), 3149–3159.
46. Kawalekar, O.U., O'Connor, R.S., Fraietta, J.A., Guo, L., McGettigan, S.E., Posey, A.D. Jr., et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44:2 (2016), 380–390.
47. Kershaw, M.H., Westwood, J.A., Parker, L.L., Wang, G., Eshhar, Z., Mavroukakis, S.A., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12:20 Pt 1 (2006), 6106–6115.
48. Kieback, E., Charo, J., Sommermeyer, D., Blankenstein, T., Uckert, W., A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc Natl Acad Sci U S A 105:2 (2008), 623–628.
49. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., Maric, I., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:12 (2012), 2709–2720.
50. Koneru, M., O'Cearbhaill, R., Pendharkar, S., Spriggs, D.R., Brentjens, R.J., A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med, 13, 2015, 102.
51. Koneru, M., Purdon, T.J., Spriggs, D., Koneru, S., Brentjens, R.J., IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors. Oncoimmunology, 4(3), 2015, e994446.
52. Lamers, C.H., Sleijfer, S., van Steenbergen, S., van Elzakker, P., van Krimpen, B., Groot, C., et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 21:4 (2013), 904–912.
53. Lamers, C.H., Sleijfer, S., Vulto, A.G., Kruit, W.H., Kliffen, M., Debets, R., et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24:13 (2006), e20–e22.
54. Lanitis, E., Poussin, M., Kattenhoff, A.W., Song, D., Sandaltzopoulos, R., June, C.H., et al. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res 1:1 (2013), 43–53.
55. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:9967 (2015), 517–528.
56. Linette, G.P., Stadtmauer, E.A., Maus, M.V., Rapoport, A.P., Levine, B.L., Emery, L., et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122:6 (2013), 863–871.
57. Liu, X., Pu, Y., Cron, K., Deng, L., Kline, J., Frazier, W.A., et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 21:10 (2015), 1209–1215.
58. Liu, X., Ranganathan, R., Jiang, S., Fang, C., Sun, J., Kim, S., et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res 76:6 (2016), 1578–1590.
59. Long, K.B., Beatty, G.L., Harnessing the antitumor potential of macrophages for cancer immunotherapy. Oncoimmunology, 2(12), 2013, e26860.
60. Long, K.B., Gladney, W.L., Tooker, G.M., Graham, K., Fraietta, J.A., Beatty, G.L., IFNgamma and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discov 6:4 (2016), 400–413.
61. Long, A.H., Haso, W.M., Shern, J.F., Wanhainen, K.M., Murgai, M., Ingaramo, M., et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21:6 (2015), 581–590.
62. Louis, C.U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G.D., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118:23 (2011), 6050–6056.
63. Maher, J., Wilkie, S., CAR mechanics: driving T cells into the MUC of cancer. Cancer Res 69:11 (2009), 4559–4562.
64. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:16 (2014), 1507–1517.
65. Maus, M.V., Haas, A.R., Beatty, G.L., Albelda, S.M., Levine, B.L., Liu, X., et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 1 (2013), 26–31.
66. Mellor, A.L., Munn, D.H., Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 8:1 (2008), 74–80.
67. Mlecnik, B., Bindea, G., Angell, H.K., Sasso, M.S., Obenauf, A.C., Fredriksen, T., et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med, 6(228), 2014, 228ra237.
68. Moon, E.K., Carpenito, C., Sun, J., Wang, L.C., Kapoor, V., Predina, J., et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 17:14 (2011), 4719–4730.
69. Moon, E.K., Wang, L.C., Dolfi, D.V., Wilson, C.B., Ranganathan, R., Sun, J., et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 20:16 (2014), 4262–4273.
70. Morello, A., Sadelain, M., Adusumilli, P.S., Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov 6:2 (2016), 133–146.
71. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., Rosenberg, S.A., Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:4 (2010), 843–851.
72. Morsut, L., Roybal, K.T., Xiong, X., Gordley, R.M., Coyle, S.M., Thomson, M., et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell 164:4 (2016), 780–791.
73. Mukasa, A., Wykosky, J., Ligon, K.L., Chin, L., Cavenee, W.K., Furnari, F., Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci U S A 107:6 (2010), 2616–2621.
74. Munn, D.H., Mellor, A.L., Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117:5 (2007), 1147–1154.
75. Mussai, F., Egan, S., Hunter, S., Webber, H., Fisher, J., Wheat, R., et al. Neuroblastoma arginase activity creates an immunosuppressive microenvironment that impairs autologous and engineered immunity. Cancer Res 75:15 (2015), 3043–3053.
76. Ninomiya, S., Narala, N., Huye, L., Yagyu, S., Savoldo, B., Dotti, G., et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125:25 (2015), 3905–3916.
77. O'Rourke, D., Desai, A., Morrissette, J., Martinez-Lage, M., Nasrallah, M., Brem, S., et al. IMCT-15 pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII + glioblastoma. Neuro-Oncology 17 (2015), v110–v111.
78. Palazon, A., Aragones, J., Morales-Kastresana, A., de Landazuri, M.O., Melero, I., Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res 18:5 (2011), 1207–1213.
79. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:4 (2012), 252–264.
80. Park, J.R., Digiusto, D.L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 15:4 (2007), 825–833.
81. Peng, W., Chen, J.Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M.T., et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6:2 (2016), 202–216.
82. Porter, D.L., Hwang, W.T., Frey, N.V., Lacey, S.F., Shaw, P.A., Loren, A.W., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med, 7(303), 2015, 303ra139.
83. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., June, C.H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:8 (2011), 725–733.
84. Pule, M.A., Savoldo, B., Myers, G.D., Rossig, C., Russell, H.V., Dotti, G., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:11 (2008), 1264–1270.
85. Pyonteck, S.M., Akkari, L., Schuhmacher, A.J., Bowman, R.L., Sevenich, L., Quail, D.F., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19:10 (2013), 1264–1272.
86. Qian, B.Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L.R., et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475:7355 (2011), 222–225.
87. Riddell, S.R., Elliott, M., Lewinsohn, D.A., Gilbert, M.J., Wilson, L., Manley, S.A., et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2:2 (1996), 216–223.
88. Robbins, P.F., Morgan, R.A., Feldman, S.A., Yang, J.C., Sherry, R.M., Dudley, M.E., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:7 (2011), 917–924.
89. Rosenberg, S.A., Restifo, N.P., Yang, J.C., Morgan, R.A., Dudley, M.E., Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:4 (2008), 299–308.
90. Sampson, J.H., Archer, G.E., Mitchell, D.A., Heimberger, A.B., Herndon, J.E. 2nd, Lally-Goss, D., et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 8:10 (2009), 2773–2779.
91. Sampson, J.H., Choi, B.D., Sanchez-Perez, L., Suryadevara, C.M., Snyder, D.J., Flores, C.T., et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 20:4 (2014), 972–984.
92. Schumacher, T.N., T-cell-receptor gene therapy. Nat Rev Immunol 2:7 (2002), 512–519.
93. Shrimali, R.K., Yu, Z., Theoret, M.R., Chinnasamy, D., Restifo, N.P., Rosenberg, S.A., Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 70:15 (2012), 6171–6180.
94. Singh, N., Perazzelli, J., Grupp, S.A., Barrett, D.M., Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med, 8(320), 2016, 320ra323.
95. Sparmann, A., Bar-Sagi, D., Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6:5 (2004), 447–458.
96. Spear, P., Barber, A., Rynda-Apple, A., Sentman, C.L., Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-gamma and GM-CSF. J Immunol 188:12 (2012), 6389–6398.
97. Spranger, S., Bao, R., Gajewski, T.F., Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523:7559 (2015), 231–235.
98. Straathof, K.C., Pule, M.A., Yotnda, P., Dotti, G., Vanin, E.F., Brenner, M.K., et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 105:11 (2005), 4247–4254.
99. Stromnes, I.M., Brockenbrough, J.S., Izeradjene, K., Carlson, M.A., Cuevas, C., Simmons, R.M., et al. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut, 2014.
100. Stromnes, I.M., Schmitt, T.M., Hulbert, A., Brockenbrough, J.S., Nguyen, H.N., Cuevas, C., et al. T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell 28:5 (2015), 638–652.
101. Tanyi, J.L., Haas, A.R., Beatty, G.L., Morgan, M.A., Stashwick, C.J., O'Hara, M.H., et al. Abstract CT105: safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers. Cancer Res, 75, 2015, CT105.
102. Tseng, D., Volkmer, J.P., Willingham, S.B., Contreras-Trujillo, H., Fathman, J.W., Fernhoff, N.B., et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A 110:27 (2013), 11103–11108.
103. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:7528 (2014), 568–571.
104. Vogler, I., Newrzela, S., Hartmann, S., Schneider, N., von Laer, D., Koehl, U., et al. An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol Ther 18:7 (2010), 1330–1338.
105. Wang, X., Chang, W.C., Wong, C.W., Colcher, D., Sherman, M., Ostberg, J.R., et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118:5 (2011), 1255–1263.
106. Wang, G., Lu, X., Dey, P., Deng, P., Wu, C.C., Jiang, S., et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov 6:1 (2016), 80–95.
107. Willingham, S.B., Volkmer, J.P., Gentles, A.J., Sahoo, D., Dalerba, P., Mitra, S.S., et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 109:17 (2012), 6662–6667.
108. Zhao, Y., Moon, E., Carpenito, C., Paulos, C.M., Liu, X., Brennan, A.L., et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 70:22 (2010), 9053–9061.
109. Zou, W., Wolchok, J.D., Chen, L., PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med, 8(328), 2016, 328rv324.